Filtros de búsqueda

Lista de obras de Manuel Hidalgo

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry ⬇️

artículo científico publicado el 27 de agosto de 2012

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer ⬇️

artículo científico publicado el 14 de junio de 2011

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

artículo científico publicado en 2010

A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma

artículo científico publicado en 2010

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

artículo científico publicado en 2009

A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer

artículo científico publicado en 2010

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

artículo científico publicado en 2015

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties

artículo científico publicado en 2004

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

artículo científico publicado en 2002

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies

artículo científico publicado en 2002

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer

artículo científico publicado en 2006

A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors

scientific article published on 01 July 2006

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

artículo científico publicado en 2012

A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.

artículo científico publicado en 2014

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

artículo científico publicado en 2007

A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay

artículo científico publicado en 2006

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells

artículo científico publicado en 2009

Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma

scientific article published on 01 July 2008

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

artículo científico publicado en 2014

Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy

artículo científico publicado en 2008

Addressing the challenges of pancreatic cancer: future directions for improving outcomes

artículo científico publicado en 2014

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

artículo científico publicado en 2004

An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity

artículo científico publicado en 2012

An in vivo platform for translational drug development in pancreatic cancer

scientific article published on 01 August 2006

An introduction to pancreatic adenocarcinoma genetics, pathology and therapy.

artículo científico publicado en 2002

Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors

artículo científico publicado en 2007

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

artículo científico publicado en 2008

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

artículo científico publicado en 2009

Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics

artículo científico publicado en 2010

Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis

artículo científico publicado en 2005

Assessment of celecoxib pharmacodynamics in pancreatic cancer

artículo científico publicado en 2006

Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer

artículo científico publicado en 2007

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration

artículo científico publicado en 2006

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

artículo científico publicado en 2007

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

artículo científico publicado en 2020

Benzoylphenylurea sulfur analogues with potent antitumor activity

artículo científico publicado en 2006

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

artículo científico publicado en 2006

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

artículo científico publicado en 2012

Blockade of epidermal growth factor receptor (EGFR) activity.

artículo científico publicado en 2005

C-fos assessment as a marker of anti-epidermal growth factor receptor effect

artículo científico publicado en 2006

COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study

artículo científico publicado en 2020

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

scientific article published on 01 December 2006

Cetuximab in squamous cell carcinoma of the head and neck.

artículo científico publicado en 2006

Characterizing DNA methylation patterns in pancreatic cancer genome.

artículo científico publicado en 2009

Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling.

artículo científico publicado en 2014

Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?

artículo científico publicado en 2008

Colorectal cancer classification based on gene expression is not associated with FOLFIRI response

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

artículo científico publicado en 2009

Comparative analyses of the β-tubulin gene and molecular modeling reveal molecular insight into the colchicine resistance in kinetoplastids organisms

artículo científico publicado en 2013

Consensus on the treatment of pancreatic cancer in Spain.

artículo científico publicado en 2009

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

artículo científico publicado en 2012

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer

artículo científico publicado en 2008

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

artículo científico publicado en 2008

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma

artículo científico publicado en 2013

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models ⬇️

artículo científico publicado el 1 de octubre de 2011

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

artículo científico publicado en 2009

Design, synthesis and biological evaluation of novel riccardiphenol analogs

artículo científico publicado en 2005

Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry

artículo científico publicado en 2008

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

artículo científico publicado en 2003

Development of matrix metalloproteinase inhibitors in cancer therapy

artículo científico publicado en 2002

Development of matrix metalloproteinase inhibitors in cancer therapy.

artículo científico publicado en 2001

Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).

artículo científico publicado en 2003

Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer

artículo científico publicado en 2007

Dietary gallic acid and anthocyanin cytotoxicity on human fibrosarcoma HT1080 cells. A study on the mode of action

artículo científico publicado en 2014

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

artículo científico publicado en 2007

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

artículo científico publicado en 2013

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.

artículo científico publicado en 2007

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer

artículo científico publicado en 2007

EGFR inhibitor-mediated apoptosis in solid tumors.

artículo científico publicado en 2007

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

artículo científico publicado en 2013

Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome.

artículo científico publicado en 2011

Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update.

artículo científico publicado en 2015

Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

artículo científico publicado en 2009

Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity

artículo científico publicado en 2003

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

artículo científico publicado en 2004

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents

artículo científico publicado en 2005

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

artículo científico publicado en 2008

Examining the utility of patient-derived xenograft mouse models

artículo científico publicado en 2015

Exploiting novel molecular targets in gastrointestinal cancers.

artículo científico publicado en 2007

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

artículo científico publicado en 2011

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

scientific article published on 01 August 2007

Fenugreek: a naturally occurring edible spice as an anticancer agent

artículo científico publicado en 2009

First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According toKRASStatus from a Spanish TTD Group Study ⬇️

artículo científico publicado el 23 de febrero de 2012

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).

artículo científico publicado en 2009

From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin ⬇️

artículo científico publicado el 7 de noviembre de 2011

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

artículo científico publicado en 2011

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib

scientific article published on 22 August 2007

Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics ⬇️

artículo científico publicado el 30 de julio de 2012

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

artículo científico publicado en 2013

Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers

artículo científico publicado en 2005

Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.

artículo científico publicado en 2011

Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy

artículo científico publicado en 2005

Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.

artículo científico publicado en 2003

Importance of family history in colorectal cancer clinical practice

artículo científico publicado en 2010

In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent

artículo científico publicado en 2005

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

artículo científico publicado en 2013

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

artículo científico publicado en 2015

Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction

artículo científico publicado en 2011

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

artículo científico publicado en 2004

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

artículo científico publicado en 2002

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

artículo científico publicado en 2014

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

artículo científico publicado en 2012

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

artículo científico publicado en 2010

Intracellular autofluorescence: a biomarker for epithelial cancer stem cells

artículo científico publicado en 2014

Intracellular signal transduction pathway proteins as targets for cancer therapy.

artículo científico publicado en 2005

Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literature

artículo científico publicado en 2009

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

artículo científico publicado en 2013

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

artículo científico publicado en 2013

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts

artículo científico publicado en 2011

Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma

scientific article published on 01 October 2004

Matrix metalloproteinase inhibitors: how can we optimize their development?

scientific article published on 01 March 2001

Matrix metalloproteinase-2 contributes to cancer cell migration on collagen

Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer.

artículo científico publicado en 2014

Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells

artículo científico publicado en 2013

Methylation alterations are not a major cause of PTTG1 misregulation.

artículo científico publicado en 2008

Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment.

artículo científico publicado en 2015

Molecular basis of colorrectal cancer: towards an individualized management?

artículo científico publicado en 2011

Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.

artículo científico publicado en 2006

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.

artículo científico publicado en 2014

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

artículo científico publicado en 2004

Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts

artículo científico publicado en 2013

Mycophenolate mofetil: An update

artículo científico publicado en 2009

NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen

artículo científico publicado en 2004

Nab-paclitaxel: a flattering facelift

artículo científico publicado en 2014

New insights into pancreatic cancer biology ⬇️

artículo científico publicado el 1 de septiembre de 2012

New scaffolds for the design of selective estrogen receptor modulators

artículo científico publicado en 2008

New target, new drug, old paradigm

artículo científico publicado en 2004

New targets for cancer chemotherapy

artículo científico publicado en 2002

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists

artículo científico publicado en 2004

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

artículo científico publicado en 2015

Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy

artículo científico publicado en 2011

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

artículo científico publicado en 2013

Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy

artículo científico publicado en 2008

Novel targets in solid tumors: MEK inhibitors.

artículo científico publicado en 2006

Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays

scientific article published on 01 February 2007

Pancreatic cancer

artículo científico publicado en 2002

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

artículo científico

Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

artículo científico publicado en 2007

Patient-derived xenograft models: an emerging platform for translational cancer research

artículo científico publicado en 2014

Personalized chemotherapy profiling using cancer cell lines from selectable mice

artículo científico publicado en 2013

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer ⬇️

artículo científico publicado el 6 de diciembre de 2010

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

artículo científico publicado en 2003

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

artículo científico publicado en 2003

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib

artículo científico publicado en 2006

Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer

artículo científico publicado en 2014

Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

artículo científico publicado en 2006

Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors

scientific article published on 25 October 2006

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors

artículo científico publicado en 2015

Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.

artículo científico publicado en 2013

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2010

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel

artículo científico publicado en 2001

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.

artículo científico publicado en 2001

Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors

artículo científico publicado en 2007

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

artículo científico publicado en 2009

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

artículo científico publicado en 2001

Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors

artículo científico publicado en 2014

Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer

artículo científico publicado en 2012

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors

artículo científico publicado en 2006

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

artículo científico publicado en 2008

Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors

artículo científico publicado en 2014

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

artículo científico publicado en 2011

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities

artículo científico publicado en 2004

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

artículo científico publicado en 2008

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

artículo científico publicado en 2009

Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors

artículo científico publicado en 2006

Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer

artículo científico publicado en 2016

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

artículo científico publicado en 2005

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)

artículo científico publicado en 2014

Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue

artículo científico publicado en 2006

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

scientific article published on 15 December 2011

Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.

artículo científico publicado en 2004

Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology

artículo científico publicado en 2013

Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft ⬇️

artículo científico publicado el 19 de diciembre de 2011

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma

artículo científico publicado en 2010

Progress in the development and acquisition of anticancer agents from marine sources.

artículo científico publicado en 2003

Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity

artículo científico publicado en 2005

Promising developments in targeted therapies for non-small-cell lung cancer

artículo científico publicado en 2002

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

artículo científico publicado en 2004

Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway

artículo científico publicado en 2004

Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.

artículo científico publicado en 2014

Retrospective study assessing the role of MRI in the diagnostic procedures for early breast carcinoma: a correlation of new foci in the MRI with tumor pathological features

artículo científico publicado en 2012

SEOM clinical guidelines for the treatment of pancreatic cancer

scientific article published on 01 August 2011

SMAD4 in early onset colorectal cancer

scientific article published on 29 April 2010

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

artículo científico

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

artículo científico publicado en 2015

Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry

artículo científico publicado en 2003

Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry

artículo científico publicado en 2005

Stromal Cell-Derived Factor 1α Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer ⬇️

artículo científico publicado el 1 de agosto de 2012

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer ⬇️

artículo científico publicado el 1 de noviembre de 2012

Surgical management of hereditary colorectal cancer: surgery based on molecular analysis and family history

artículo científico publicado en 2009

Synthesis and antitumor evaluation of benzoylphenylurea analogs

artículo científico publicado en 2004

Targeting mTOR for cancer treatment

scientific article published on 01 January 2006

Targeting mTOR for cancer treatment.

artículo científico publicado en 2006

The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre

artículo científico publicado en 2013

The Development of rapamycin as an orphan drug

scientific article published on 01 February 2007

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors ⬇️

artículo científico publicado el 31 de julio de 2013

The V599E BRAF mutation is uncommon in biliary tract cancers

artículo científico publicado en 2004

The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models

artículo científico publicado en 2012

The hedgehog pathway and pancreatic cancer

scientific article published on 01 November 2009

The inverted pyramid of biomarker-driven trials

artículo científico publicado en 2011

The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells

artículo científico publicado en 2015

The winning formulation: the development of paclitaxel in pancreatic cancer

artículo científico publicado en 2013

Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function

artículo científico publicado en 2015

Transcriptional dissection of pancreatic tumors engrafted in mice.

artículo científico publicado en 2014

Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas

artículo científico

Treating cancer by blocking cell signals

artículo científico publicado en 2005

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

artículo científico publicado en 2002

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

artículo científico publicado en 2011

Tumor-initiating cells are rare in many human tumors

artículo científico publicado en 2010

Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors.

artículo científico publicado en 2013

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma

artículo científico publicado en 2007

Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.

artículo científico publicado en 2009

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

artículo científico publicado en 2009

[Influence of age on the surgical treatment of lynch syndrome]

artículo científico publicado en 2010

[Surgical management of familial colorectal cancer type X]

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda